For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of Dermatology ...

The involvement can be so widespread as to involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). While the hair loss of AA itself is not usually symptomatic ...

How do you see the future of combination therapies, using baricitinib in conjunction with other treatments, for pediatric alopecia areata? As you know, in the real world, we don't have to do ...

Adolescents with severe or very severe alopecia areata (AA) were able to regrow hair, some with a 90% improvement in hair loss, after taking the Janus kinase inhibitor baricitinib daily ...

including alopecia totalis/universalis) in a phase 3 trial. Three hundred thirty patients were randomly assigned to receive either daily oral ivarmacitinib (4 or 8mg) or placebo for 24 weeks (109 ...

Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients (aged 12-18) with severe alopecia areata (AA) showed clinically ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...

TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of ...

baricitinib 2 mg or placebo. The primary endpoint of this study was a Severity of Alopecia Tool (SALT) score ≤20 (i.e., 80% or more scalp hair coverage) at Week 36. At the start of the study, patients ...

At week 36, 42.4 and 27.4% of patients receiving baricitinib 4mg and baricitinib 2mg, respectively, achieved a SALT score of less than or equal to 20 compared with 4.5% of patients receiving placebo.